Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Li B et al. – The triple mutant, which was demonstrated to efficiently initiate both caspase–dependent and –independent apoptosis, exhibited potent in vivo therapeutic efficacy, even in the rituximab–resistant lymphoma model, suggesting that it might be a promising therapeutic agent for B–cell lymphomas.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address